- Home
- NMI vs ADAG Comparison
NMI vs ADAG Comparison
Compare NMI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | ADAG |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.9M | 90.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMI | ADAG |
|---|---|---|
| Price | $10.18 | $3.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 28.4K | ★ 252.9K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $1.30 |
| 52 Week High | $10.05 | $3.26 |
Technical Indicators
Market Signals| Indicator | NMI | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 61.98 |
| Support Level | $10.06 | $2.70 |
| Resistance Level | $10.25 | $3.11 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 79.07 | 70.00 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.